Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy

Completed · Phase 2/Phase 3

Conditions studied: Diabetic Peripheral Neuropathy

In brief

The purpose of this study is to see if an investigational drug known as the lidocaine 5% patch is safe and effective in reducing the symptoms of diabetic neuropathy, to examine how topical lidocaine affects the nerve endings, and to determine whether treatment with the lidocaine patch can prevent the potential progression to chronic diabetic neuropathy pain in subjects who did not report pain at the start of the study.

Key facts

Study ID

NCT01086150

Run by

Albany Medical College

People needed

51

Starts

2009-10-01

Expected to finish

2015-10-01

Last updated by the study team

2020-06-11

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Group 1: 18-70 years of age, non-diabetic with no nervous system disease (healthy control group)
• Group 2: 18-70 years of age with Type I or Type II diabetes with significantly painful diabetic neuropathy (VAS > 40mm at Baseline)
• Group 3: 18-70 years of age with Type I or Type II diabetes with non- painful or insignificantly painful diabetic neuropathy (VAS < 40mm at Baseline)

You may not qualify if…

• History of clinically significant liver disease, serious peripheral vascular disease, a blood clotting disorder, or any other medical condition felt to be exclusionary by the investigator
• Allergy to lidocaine
• Unwillingness to sign informed consent or any other reasons for which the investigator feels the subject cannot complete the study
• Women who are pregnant, breastfeeding or trying to become pregnant
• History of slow-healing diabetic foot ulcers
• Current skin or soft tissue lesions on the foot that will interfere with application of the lidocaine patch and or skin biopsies
• Subjects taking Class I antiarrhythmics
• HgA1c > 11%
• Active cancer within the previous two years except treated basal cell carcinoma of the skin
• Co-morbidities that can produce neuropathy
• Subjects taking sodium channel blockers within one week of study treatment and throughout the study
• Subjects taking any other experimental drugs within 30 days prior to Screening Visit (Visit 1)
• Application of lidocaine patch to either foot within two weeks of Screening Visit (Visit 1)

Where it is running

• Albany Medical College — Albany, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.